The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRB..L Regulatory News (RB.)

  • There is currently no data for RB.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Circular to Shareholders and Notice of GM

5 May 2017 16:21

RNS Number : 3810E
Reckitt Benckiser Group PLC
05 May 2017
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

FOR IMMEDIATE RELEASE

5 May 2017

 

Reckitt Benckiser Group plc

Acquisition of Mead Johnson Nutrition Company

On 10 February 2017, Reckitt Benckiser Group plc ("RB") announced that it had reached agreement with Mead Johnson Nutrition Company (NYSE:MJN) ("Mead Johnson") on the terms of a recommended merger under which Mead Johnson shareholders will receive $90 in cash for each share of common stock, valuing the total equity at $16.7 billion.

Due to its size, the proposed acquisition constitutes a Class 1 transaction for RB under the UK Listing Rules. RB is pleased to announce that the circular convening a meeting of its shareholders to approve the acquisition has been published today on RB's website at www.rb.com under the Investors section and will shortly be posted to shareholders. The Circular is available for inspection at RB's registered office and has also been submitted to the National Storage Mechanism and will shortly be available for inspection at www.Hemscott.com/nsm.do.

The meeting to approve the transaction is scheduled to be held at the Auditorium of Deutsche Bank AG, Ground Floor, Winchester House, 75 London Wall, London EC2N 2DB at 3.00 p.m. on 31 May 2017.

The acquisition is also subject to approval by the shareholders of Mead Johnson and the receipt of one outstanding regulatory approval. The transaction is expected to be completed by the end of Q3 2017.

 

Enquiries / advisers

For further information, please contact:

RB +44 (0)1753 217 800

Richard Joyce - SVP, Investor Relations

Patty O'Hayer - Director, External Relations and Government Affairs

Brunswick +44 (0) 207 404 5959

Gabrielle Silver / David Litterick

Robey Warshaw and Bank of America Merrill Lynch are acting as joint lead financial advisers to RB. Deutsche Bank is acting as financial adviser, corporate broker and sponsor to RB. HSBC is acting as financial adviser to RB.

Davis Polk & Wardwell LLP and Linklaters LLP are retained as legal advisers to RB.

Further information

The Mead Johnson equity value is calculated based on 183,635,708 basic shares outstanding and estimated total dilution from stock options, restricted share units and performance share awards of 1,775,240 shares as at 13 April 2017. The estimated dilution from stock options has been calculated using the treasury stock method.

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

Important notice

This announcement is not for release, publication or distribution directly or indirectly, in whole or in part, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. This announcement has been prepared for the purposes of complying with applicable law and regulation in the United Kingdom and the information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws and regulations of any jurisdiction outside of the United Kingdom.

Important notice about financial advisers

Robey Warshaw LLP ("Robey Warshaw"), which is authorised and regulated by the Financial Conduct Authority, is acting exclusively for RB and no one else in connection with the contents of this announcement and will not be responsible to anyone other than RB for providing the protections afforded to its clients or for providing advice in connection with the contents of this announcement or any matter referred to in this announcement.

Merrill Lynch International ("BofA Merrill Lynch") is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom. BofA Merrill Lynch is acting exclusively for RB and no one else in connection with the contents of this announcement. In connection with such matters, BofA Merrill Lynch, its affiliates and their respective directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to any other person for providing the protections afforded to their clients or for providing advice in connection with this announcement or any other matter referred to herein.

Deutsche Bank AG, London Branch ("Deutsche Bank") is authorised under German Banking Law (competent authority: European Central Bank) and, in the United Kingdom, by the Prudential Regulation Authority. It is subject to supervision by the European Central Bank and by BaFin, Germany's Federal Financial Supervisory Authority, and is subject to limited regulation in the United Kingdom by the Prudential Regulation Authority and Financial Conduct Authority. Details about the extent of its authorisation and regulation by the Prudential Regulation Authority, and regulation by the Financial Conduct Authority are available on request or from www.db.com/en/content/eu_disclosures.html. Deutsche Bank is acting as financial adviser, corporate broker and sponsor to RB and no one else in connection with the proposed acquisition or the contents of this announcement and will not be responsible to anyone other than RB for providing the protections afforded to clients of Deutsche Bank or for providing advice in relation to the proposed acquisition or any other matters referred to herein.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOGUVAVRBBAVRAR
Date   Source Headline
31st Mar 202110:00 amRNSRB rebrands as Reckitt
26th Mar 202112:30 pmRNSDirector/PDMR Shareholding
17th Mar 20213:00 pmRNSDirector/PDMR Shareholding
4th Mar 20212:30 pmRNSDirector/PDMR Shareholding
3rd Mar 202110:00 amRNSDirector/PDMR Shareholding
1st Mar 20213:00 pmRNSDirector/PDMR Shareholding
1st Mar 20212:16 pmRNSTotal Voting Rights
25th Feb 20213:20 pmRNSDirector/PDMR Shareholding
24th Feb 20217:01 amRNSDisposal
24th Feb 20217:01 amRNSAcquisition
24th Feb 20217:00 amRNSFinal Results
1st Feb 202111:42 amRNSTotal Voting Rights
4th Jan 202112:39 pmRNSTotal Voting Rights
30th Dec 20209:21 amRNSTR-1: Notification of major holdings
17th Dec 202010:45 amRNSDirectorate Change
1st Dec 202011:30 amRNSTotal Voting Rights
25th Nov 202011:30 amRNSDirector/PDMR Shareholding
23rd Nov 20204:30 pmRNSDirector/PDMR Shareholding
2nd Nov 202011:10 amRNSTotal Voting Rights
21st Oct 20202:00 pmRNSDirector/PDMR Shareholding
20th Oct 20204:35 pmRNSPrice Monitoring Extension
20th Oct 20207:00 amRNS3rd Quarter Results
7th Oct 20203:00 pmRNSDirector Declaration
5th Oct 20204:00 pmRNSDirector/PDMR Shareholding
1st Oct 20202:34 pmRNSDirector/PDMR Shareholding
1st Oct 202011:38 amRNSTotal Voting Rights
1st Sep 202010:22 amRNSTotal Voting Rights
26th Aug 20201:05 pmRNSDisclosure of rights attached to equity shares
25th Aug 20204:00 pmRNSDirector/PDMR Shareholding
3rd Aug 202012:08 pmRNSTotal Voting Rights
28th Jul 20207:00 amRNSHalf-year Report
1st Jul 20209:17 amRNSTotal Voting Rights
30th Jun 20205:00 pmRNSDirector Declaration
23rd Jun 202010:00 amRNSDirectorate Change
5th Jun 20204:30 pmRNSDirector/PDMR Shareholding
1st Jun 202011:01 amRNSTotal Voting Rights
29th May 20204:41 pmRNSSecond Price Monitoring Extn
29th May 20204:36 pmRNSPrice Monitoring Extension
29th May 20204:30 pmRNSDirector/PDMR Shareholding
29th May 202012:20 pmRNSDirector/PDMR Shareholding
28th May 20202:29 pmRNSDirector/PDMR Shareholding
13th May 20205:46 pmRNSDirector/PDMR Shareholding
13th May 20202:07 pmRNSPublication of Offering Memorandum
12th May 20206:01 pmRNSIssue of Debt
12th May 20204:55 pmRNSResult of AGM
12th May 20204:15 pmRNSDirectorate Change
4th May 20202:10 pmRNSDirector/PDMR Shareholding
1st May 20204:41 pmRNSDirector/PDMR Shareholding
1st May 202011:38 amRNSTotal Voting Rights
30th Apr 20207:00 amRNSQ1 2020 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.